Stem Cell Breakthroughs and Investor Fortunes

Start your Free Tomorrow In Review Preview - Sign Up Here:

Jul 8th, 2009 | By | Category: Featured, Technology
leadimage

Something happened last week that I predicted many months ago. Big Pharm initiated a collaboration with one of the stem cell companies I recommended to my Breakthrough Technology Alert readers. Specifically, Geron Corp. (NASDAQ: GERN) announced a partnership with GE Healthcare.

The deal is to develop and sell drug-discovery technologies derived from two stem cell lines approved by the Bush administration. The stock rose over 10%, adding about $70 million to Geron’s capitalization.

I don’t write this to crow about being right. I write this because it is critically important that you understand that this is just the tip of the iceberg. For anybody familiar with the way pharma interacts with disruptive startups, it was inevitable. New products from Big Pharma have slowed to a trickle in recent years. The old platforms have largely played out. Slowly, recognition is dawning on the world’s medical giants that it’s time to invest in the most disruptive technology the world has ever seen — stem cell technologies.

Let’s look at the implications.

Pharm is a lumbering behemoth. It may take years for the industry to change focus, but it spews cash wherever it turns. The Geron deal is only the first, so let’s consider what’s next.

Geron has had years to cultivate its Big Pharm contacts, but Geron’s founder, Dr. Michael West, was busy creating and acquiring his own stem cell lines. His inventory, as a result, dwarfs Geron’s.

He has, in fact, most of the stem cell lines approved by the Obama administration’s new funding guidelines. They comprise, remarkably, more than 50% of all known eSC lines. At last count, he had over 200 lines, and 88 had important genetic diseases.

These cell lines, incidentally, were acquired from genetic screeners who help parents who carry genetic diseases assure that they do not pass them onto their children. They include cystic fibrosis, Huntington’s, muscular dystrophy and breast cancer.

Ironically, these cell lines hold the promise of producing treatments for birth defects that currently motivate a significant percentage of abortions. This means, of course, that the utilization of these cells may produce cures that reduce abortion rates.

The story does not end there. West’s ACTCellerate platform is producing the tools for potentiating stem cells into different cell types. Currently, West knows how to turn stem cells, including induced pluripotent stem cells created from adult cells, into more than 140 cell types. Recently, for example, he announced the ability to program cells to repair cartilage and connective tissues.

Therefore, the real number of cell lines that he can produce is in excess of 200 eSC lines times 140 SC types, which is over 28,000 cell types. If only a fraction of these cell types have drug discovery potential, West will do very well, indeed.

Yours for transformational profits,
Patrick Cox

July 8, 2009


Author Image for Patrick Cox

Patrick Cox

Patrick Cox has lived deep inside the world of transformative technologies for over 25 years. In the 1980s, he worked in computer software development and manufacturing. By the mid-1990s, he worked as a consultant for Netscape — the company that handled 90% of all Internet browsing traffic at the time. InfoWorld and USA Today have featured Patrick's research numerous times. He's also appeared on Crossfire and Nightline. Patrick has been quoted by The Wall Street Journal and Reason magazine. His expertise brought him to Agora Financial, where he now heads Breakthrough Technology Alert, the only place you'll find the truly transformational technologies that offer exponential gains.

Start your free Tomorrow in Review email subscription...

  

We Will Not Share Your Email Address
We Value Your Privacy

Tags:
ShareThis
Print This Post Print This Post

Leave Comment

By submitting your comment you agree to adhere to our comment policy.